Kaladhar B. Reddy, Ph.D.

Kaladhar B. Reddy, Ph.D.



Kaladhar B. Reddy, Ph.D.

Office Address

Department of Pathology
Wayne State University School of Medicine
540 East Canfield Avenue
Detroit, MI 48201

Administrative Contact

Brenda Batts
Phone: (313) 577-1102

Position Title


Education Training

Ph.D. (1984): Osmania University, Hyderabad, AP, India

Postdoctoral Fellowship
1984-1988: University of Medicine and Dentistry of New Jersey, Newark, NJ, USA
1988-1990: The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Areas of Interest

Cancer stem cells, Breast cancer, hormones, growth factor signaling, cross-talk, and drug sensitivity



1.  Xu L, Yin S, Banerjee S, Sarkar F, and Reddy KB, 2011,  Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor cells. Molecular Cancer Therapeutics 10: 550-557.

2. Yin S, Xu L, Bandyopadhyay S, Sethi S, and Reddy KB, 2011,Cisplatin and TRAIL Enhance Breast Cancer Stem Cell Death. Int. J Oncology 39: 891 898.
3. Reddy KB , 2011, Triple-Negative Breast Cancers: An updated review on treatment options. Current Oncology 18: 173-179.
4. Wong C, Wang X, Smith D, Reddy KB, Chen S: AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res. and Treat. 134: 671-81, 2012.
*5. Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar F, Sethi S and Reddy KB: Tumor Initiating Cells and FZD8 play a major role in drug resistance in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 12: 491-498, 2013 [this paper was featured as a highlight by the editors for that issue].
6. Yin S, Rishi AK and Reddy KB: Anti-estrogen resistant breast cancers cells are sensitive to cisplatin plus TRAIL treatment. Oncology Reports 33: 1475-1480, 2015.
7. Muthu M, Somagoni MS, Cheriyan VT, Munie S, Levi E, Ashour AE, Yassin AEB, Alafeefy AM, Sochacki, Polin LA, Reddy KB, Larsen SD, Singh M, and Rishi AK: Identification and testing of novel CARP-1 functional mimetic compounds as inhibitors of non-small cell lung and triple negative breast cancers. Journal of Biomedical Nanotechnology 11: 1608-1627, 2015.
8. Reddy KB: MicroRNA (miRNA) in cancer (Review). Cancer Cell International 38: 1-6, 2015.
9. Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB and Sarkar FH: Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer (in press)


← Return to listing